Stock DMYD B DIAMYD MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Diamyd Medical AB

Equities

DMYD B

SE0005162880

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:35 03/05/2024 BST 		5-day change 1st Jan Change
11.16 SEK +4.30% Intraday chart for Diamyd Medical AB -6.22% +69.86%
04-18 Diamyd Medical Raises SEK57 Million in Rights Issue MT
04-12 Recruitment Milestone Reaches in Diamyd® Phase 3 Trial CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production
Diamyd Medical AB Reports Earnings Results for the First Quarter Ended November 30, 2023
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine Phase 3 Trial, DIAGNODE-3, for Type 1 Diabetes Is Planned for July 2024
Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea
Diamyd Medical AB Elects Karin Rosén as A New Member of the Board
Diamyd Medical Partners with Diamyd Medical to Recruit Participants for Type 1 Diabetes Prevention Trial
Diamyd Medical AB Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset
Diamyd Medical AB Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection
Diamyd Medical AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023
Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2023
Diamyd Medical AB Announces Changes of the Board
Diamyd Medical AB Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US
Diamyd Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023
Diamyd Medical AB Announces Topline Results from Remygen Trial in Individuals with Long-Term Type 1 Diabetes
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023
Diamyd Medical AB Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes
Diamyd Medical Brings Karin Rosén to Its Board of Directors
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMYD B Stock
  4. News Diamyd Medical AB
  5. Other languages